Person-reported outcome (PRO) measures for DMD clinical trials should be tied to meaningful disease milestones such as loss of ability to stand, rise from a chair, climb stairs, walk independently, raise a hand to the mouth, as well as need for non-invasive ventilation. We developed the DMD lifetime mobility scale (DMD-LMS) with data from the CINRG Duchenne natural history study, using mobility items from the PODCI, PedsQL, PedsQL NMM, pediatric and adult mobility scales of the NeuroQOL. “Successful” question items: a) differentiated between milestone groups; b) showed significant change over one-year, and c) were deemed “clinically significant” by exceeding change of 1/3 the standard deviation of the measure.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...